<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01237483</url>
  </required_header>
  <id_info>
    <org_study_id>GORTEC 2008-01</org_study_id>
    <nct_id>NCT01237483</nct_id>
  </id_info>
  <brief_title>Reirradiation and Erbitux in the HNSCC</brief_title>
  <official_title>A Phase II Study, Multicenter, to Evaluate the Efficacy and Safety of the Combination of Reirradiation - Erbitux in Subjects Previously Irradiated and With a Local Recurrent Inoperable Squamous Cell Cancer of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Oncologie Radiotherapie Tete et Cou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe Oncologie Radiotherapie Tete et Cou</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate in patients with cancer of the throat and
      recurrent inoperable a different modality treatment consisting of radiation continuously for
      5 weeks and half associated with a drug directed against a receptor on cell surfaces cancer,
      called Erbitux ®.

      The investigators hope with this shorter treatment (1.5 weeks less than the usual treatment)
      to improve the antitumor efficacy without additional toxic side effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We hope with this treatment improved antitumor efficacy without additional toxic side
      effects, while being shorter than 1.5 weeks of standard therapy. But this is an hypothesis we
      can not meet the current state of knowledge, which justifies this study.

      The main hypothesis is that this combination of reirradiation and Cetuximab give a relative
      gain of 15% complete response rate.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2010</start_date>
  <completion_date type="Actual">July 5, 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The main objective is to evaluate the complete response rate of the association re-irradiation - Erbitux ®.</measure>
    <time_frame>It will be measured by spiral CT scan or magnetic resonance imaging (MRI), 2 months after the end of treatment</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Head and Neck Cancer Squamous Cell</condition>
  <arm_group>
    <arm_group_label>Erbitux Radiotherapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Radiotherapy during 5 weeks and concurrent Erbitux once a week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erbitux</intervention_name>
    <description>To begin 7 days before radiotherapy, loading dose 400 mg / m² in the first week then 250 mg / m² weekly for the duration of radiotherapy (for a total of 7 doses including the loading dose)</description>
    <arm_group_label>Erbitux Radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with unresectable locoregional recurrence of squamous cell carcinoma in a
             previously irradiated area (at least 75% of the volume of recidivism must be in an
             area who have received at least 50 Gy)

          -  The entire tumor volume can be included in a radiation field without the total dose to
             the spinal cord more than 50 Gy (dose + dose earlier predicted)

          -  Patient with recurrent or second location in the oral cavity, oropharynx, larynx,
             hypopharynx, cervical lymph nodes or tissues, without distant metastases,

          -  Minimum 12 months after the end of radiotherapy previous

          -  WHO performance status: 0-1,

          -  Evaluable disease by RECIST V.1.1.,

          -  Age between 18 and 75 years

          -  The patient may have received prior chemotherapy for relapse for more than five weeks,

          -  The patient may have received cetuximab for the treatment of disease but not for the
             first relapse,

          -  Hematologic function: ANC ≥ 1500/mm3, Platelets ≥ 100000/mm3,

          -  Normal renal function: serum creatinine ≤ 120 µmol/l and/or creatinine clearance &gt; 60
             ml/min

          -  Normal liver function: bilirubin &lt;1.5 x ULN, alkaline phosphatase and transaminases
             &lt;2.5 x ULN,

          -  Normal cardiac function, assessed clinically. History of cardiovascular disease
             stabilized for over 12 months

          -  Cons-Lack of medical indications in the proposed treatment,

          -  The dosimetry of previous treatment should be available and the estimated dosimetry
             must be performed to check the constraints,

          -  All patients of childbearing age should receive effective contraception,

          -  Membership of a social security system (or be a beneficiary of such a plan) under the
             terms of the Act of August 9, 2004,

          -  Signed informed consent

        Exclusion Criteria:

          -  Tumors of the nasal cavity and paranasal,

          -  Tumors of other histological type,

          -  Stage IV with distant metastases or multiple tumors,

          -  Time after previous radiotherapy &lt;12 months,

          -  Less than 75% of the volume of relapse who have previously received at least 50 Gy,

          -  Any medical condition or general-cons would indicate the completion of treatment.
             Systemic disease or uncontrolled infection,

          -  History of cancer other than head and neck cancer, cutaneous basal cell, carcinoma in
             situ of the cervix

          -  Any other concurrent anticancer therapy,

          -  Patient receiving another molecule experimental

          -  Pregnant, lactating or without contraception;

          -  Persons deprived of liberty under guardianship

          -  Inability to undergo medical test for geographical, social or psychological

          -  Nasopharyngeal Neoplasms

          -  Patients with active ischemic heart disease or previous myocardial infarction within
             the last 12 months

          -  Late toxicity dermal or subcutaneous related to previous irradiation of grade&gt; 2 in
             the scale CTCAE V.4.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent MARTIN, oncologist</last_name>
    <role>Study Director</role>
    <affiliation>Centre Guillaume Le Conquérant, 76600 Le Havre, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claude TUCHAIS, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Paul Papin, 49933 Angers, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sauveur Marc ALFONSI, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Sainte Catherine, 84082 Avignon, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xu Sh SUN, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Jean Minoz, 25030 Besançon, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dominique DE RAUCOURT, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre François Baclesse, 14076 Caen, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michel LAPEYRE, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Jean Perrin, 63011 Clermond-Ferrand, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe MAINGON, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre G-F Leclerc, 21079 Dijon, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Muriel GARCIA-RAMIREZ, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Robert Boulin, 33505 Libourne, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian SIRE, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital du Scorff, 56322 Lorient, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Séverine RACADOT, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Léon Bérard, 69373 Lyon, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Véronique FAVREL, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Lyon Sud, 69495 Pierre-Benite, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Etienne BARDET, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre René Gauducheau, 44805 Nantes-St Herblain, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe LANG, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital de La Pitié Salpitrière, 75013 Paris, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isabelle TENNEVET, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Henri Becquerel, 76038 Rouen, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patricia BURBAN, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Armoricaine de Radiologie, 22015 St Brieuc, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olivier GALLOCHER, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Pasteur, 31300 Toulouse, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olivier GALLOCHER, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Polyclinique du Parc, 31078 Toulouse, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yungan TAO, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Gustave Roussy, 94805 Villejuif, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre BOISSELIER, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Val d'Aurelle 34298 Montpellier cedex</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frédéric PEYRADE, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Antoine Lacassagne 06189 NICE cedex 2</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie SALIOU, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique de l' Estuaire 44600 Pornichet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cédrik LAFOND, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Jean Bernard 72000 Le Mans</affiliation>
  </overall_official>
  <overall_official>
    <last_name>René-Jean BENSADOUN, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU 86021 Poitiers cedex</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexandre COUTTE, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens sud 80004 Amiens</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hao QIU, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU 86000 Limoges</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Florence HUGUET, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Tenon 75020 Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sébastien GUIHARD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Paul Strauss 67065 Strasbourg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xu Shan SUN, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier de Belfort Montbéliard Bd du Maréchal Juin 25200 Montbéliard</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Bretonneau</name>
      <address>
        <city>Tours Cedex 09</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2010</study_first_submitted>
  <study_first_submitted_qc>November 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2010</study_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>reirradiation with Erbitux</keyword>
  <keyword>HNSCC</keyword>
  <keyword>local recurrent inoperable Squamous Cell Cancer of the Head and Neck</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Squamous Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

